BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24039255)

  • 1. Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease.
    Hunt JM; Bethea B; Liu X; Gandjeva A; Mammen PP; Stacher E; Gandjeva MR; Parish E; Perez M; Smith L; Graham BB; Kuebler WM; Tuder RM
    Am J Physiol Lung Cell Mol Physiol; 2013 Nov; 305(10):L725-36. PubMed ID: 24039255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanical stretching of the pulmonary vein mediates pulmonary hypertension due to left heart disease by regulating SAC/MAPK pathway and the expression of IL-6 and TNF-α.
    Huang W; Liu H; Pan Y; Yang H; Lin J; Zhang H
    J Cardiothorac Surg; 2021 May; 16(1):127. PubMed ID: 33971931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.
    Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM
    Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction.
    Fayyaz AU; Edwards WD; Maleszewski JJ; Konik EA; DuBrock HM; Borlaug BA; Frantz RP; Jenkins SM; Redfield MM
    Circulation; 2018 Apr; 137(17):1796-1810. PubMed ID: 29246894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease.
    Ranchoux B; Nadeau V; Bourgeois A; Provencher S; Tremblay É; Omura J; Coté N; Abu-Alhayja'a R; Dumais V; Nachbar RT; Tastet L; Dahou A; Breuils-Bonnet S; Marette A; Pibarot P; Dupuis J; Paulin R; Boucherat O; Archer SL; Bonnet S; Potus F
    Circ Res; 2019 Aug; 125(4):449-466. PubMed ID: 31154939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent.
    Biasin V; Chwalek K; Wilhelm J; Best J; Marsh LM; Ghanim B; Klepetko W; Fink L; Schermuly RT; Weissmann N; Olschewski A; Kwapiszewska G
    Int J Biochem Cell Biol; 2014 Sep; 54():137-48. PubMed ID: 25016214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histopathological aspects of pulmonary hypertension].
    Jonigk D; Hoeper MM; Kreipe H; Länger F
    Pathologe; 2012 May; 33(3):183-91. PubMed ID: 22318487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAR-2 inhibition reverses experimental pulmonary hypertension.
    Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
    Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats.
    Sang P; Kucherenko MM; Yao J; Li Q; Simmons S; Kuebler WM; Knosalla C
    J Vis Exp; 2022 Mar; (181):. PubMed ID: 35311828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanical stretching of pulmonary vein stimulates matrix metalloproteinase-9 and transforming growth factor-β1 through stretch-activated channel/MAPK pathways in pulmonary hypertension due to left heart disease model rats.
    Zhang H; Huang W; Liu H; Zheng Y; Liao L
    PLoS One; 2020; 15(9):e0235824. PubMed ID: 32881898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevant issues in the pathology and pathobiology of pulmonary hypertension.
    Tuder RM; Archer SL; Dorfmüller P; Erzurum SC; Guignabert C; Michelakis E; Rabinovitch M; Schermuly R; Stenmark KR; Morrell NW
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D4-12. PubMed ID: 24355640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary hypertension secondary to left-heart failure involves peroxynitrite-induced downregulation of PTEN in the lung.
    Ravi Y; Selvendiran K; Naidu SK; Meduru S; Citro LA; Bognár B; Khan M; Kálai T; Hideg K; Kuppusamy P; Sai-Sudhakar CB
    Hypertension; 2013 Mar; 61(3):593-601. PubMed ID: 23339168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Circulating MicroRNA-206 Level Predicts the Severity of Pulmonary Hypertension in Patients with Left Heart Diseases.
    Jin P; Gu W; Lai Y; Zheng W; Zhou Q; Wu X
    Cell Physiol Biochem; 2017; 41(6):2150-2160. PubMed ID: 28554172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
    Levi M; Moons L; Bouché A; Shapiro SD; Collen D; Carmeliet P
    Circulation; 2001 Apr; 103(15):2014-20. PubMed ID: 11306532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term survivors of pediatric heart transplantation: an autopsy study of their pulmonary vascular disease.
    Collins MH; Darragh RK; Caldwell RL; Turrentine MW; Brown JW
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1116-25. PubMed ID: 8719459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
    Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.
    Song Y; Coleman L; Shi J; Beppu H; Sato K; Walsh K; Loscalzo J; Zhang YY
    Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H677-90. PubMed ID: 18552156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of lobar vessels to hypoxic pulmonary hypertension.
    Parks WC; Mecham RP; Crouch EC; Orton EC; Stenmark KR
    Am Rev Respir Dis; 1989 Nov; 140(5):1455-7. PubMed ID: 2817612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal models of pulmonary hypertension due to left heart disease.
    Liu SF; Yan Y
    Animal Model Exp Med; 2022 Sep; 5(3):197-206. PubMed ID: 35234367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects and Mechanism of Atorvastatin on Pulmonary Hypertension Due to Left Heart Disease.
    Wang Q; Guo YZ; Zhang YT; Xue JJ; Chen ZC; Cheng SY; Ou MD; Cheng KL; Zeng WJ
    PLoS One; 2016; 11(7):e0157171. PubMed ID: 27388289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.